| Literature DB >> 33184370 |
Heike Wanka1, Philipp Lutze1, Doreen Staar1, Katharina Bracke1, Janine Golchert1, Jörg Peters2.
Abstract
The renin-angiotensin system is known to regulate blood pressure as well as water- and electrolyte balance. An activated RAS is involved in the development of hypertension and hypertension-related organ damage. Thus, inhibitors of the RAS are protective and markedly increasing the life span of patients. In contrast, renin transcripts have been discovered encoding a cytoplasmatic renin isoform, termed renin-b, which is not harmful but may be even protective. Here we demonstrate that depletion of renin-b encoding transcripts by small interference RNA decreased ATP levels and increased basal necrosis as well as apoptosis rates. Furthermore, renin-b depletion potentiated the anoxia-induced increase of necrosis rates. Vice versa, overexpression of renin-b prevented the anoxia-induced increase of caspase-mediated apoptosis rates. Besides, cells overexpressing renin-b exhibited even reduced mitochondrial mediated apoptosis rates under anoxia, when compared with normoxic conditions, as indicated by Annexin V labeling. However, whereas the protective effect of renin-b on caspase-mediated apoptosis was completely blocked by the renin inhibitor CH732, the effect on mitochondrial-mediated apoptosis was not affected by CH732 at all. From these data we conclude that renin-b overexpression mediates cardioprotective effects under anoxia with respect to mitochondrial induced apoptosis angiotensin-independently, but with respect to caspase induced apoptosis likely in an angiotensin-dependent manner.Entities:
Year: 2020 PMID: 33184370 PMCID: PMC7661495 DOI: 10.1038/s41598-020-76712-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Renin mRNA abundance after anoxia and effect of renin siRNA. Renin-b and renin-a mRNA expression in H9c2 cells exposed to small interference RNA (siRNA) treatment under control and anoxic conditions (n = 6 independent experiments per group). All data represent mean ± SEM. Data are analyzed by Two-way ANOVA comparing the efficiency of renin downregulation as well as the effect of anoxia as indicated. *P < 0.05 versus scramble siRNA control as real control. #P < 0.05 versus normoxia.
Figure 2Metabolic and cell death analyses after renin downregulation. In renin downregulated H9c2 cells subjected to 24 h normoxic and anoxic conditions we measured (a) ATP levels (n = 8), (b) glucose consumption (n = 10), (c) extracellular lactate accumulation (n = 10), (d) necrosis rate (n = 8), (e) percentage of CaspACE-positive cells (n = 10), and (f) percentage of Annexin V (n = 8) (each independent experiments per group). All data represent mean ± SEM. Data of untreated control H9c2 are analyzed by t-test. Comparison of data for scramble control and siRNA-treated cells are analyzed by Two-way ANOVA comparing the effects of renin downregulation as well as the effect of anoxia as indicated. *P < 0.05 versus scramble siRNA control as real control. #P < 0.05 versus normoxia.
Figure 3Transcript levels of RAS relevant genes. Expression of the different renin transcripts (transgenic renin(2–9), renin(1A-9) both encoding for renin-b,renin(1–9) encoding for renin-a, angiotensinogen (AGT), ACE1 and the angiotensin receptors 1 (AT1R) and 2 (AT2R), (pro)renin receptor [(P)RR], and renin binding protein (RnBP) in pIRES control cells (white columns) and renin-b transfected cells (grey columns). All data represent mean ± SEM of n = 6 experiments. Data are analyzed by Two-way ANOVA.
Figure 4Metabolic and cell death analyses after inhibition of renin activity. H9c2 pIRES cells (control vector transfected) and ren(2–9) overexpressing H9c2 cells (renin-b cells) were subjected to 24 h normoxic and anoxic conditions without (white columns) and with renin inhibitor CH732 (grey columns). (a) ATP levels (n = 9), (b) glucose consumption (n = 8), (c) extracellular lactate accumulation (n = 7), (d) necrosis rate (n = 9), (e) percentage of CaspACE-positive cells (n = 7), and (f) percentage of Annexin V-positive cells (n = 7) were measured. All data represent mean ± SEM. Data are analyzed by Two-way ANOVA analysis comparing the effect of renin overexpression, CH732 treatment as well as the effect of anoxia as indicated. *P < 0.05 versus pIRES control. #P < 0.05 versus normoxia.
Figure 5Circulating and intracellular RAS’s. Model A describes the classical secretory RAS. ANGII is generated in the circulation and activate their specific receptors located at the cell membrane followed by activation or inhibition of specific signal transduction pathways. For simplicity ACE2, other other ANG fragments (ANG1-7, ANG IV, ANG III) as well as their receptors (such as MAS) were excluded. Model B describes the molecular basis for the circulating RAS with the expression of secretory renin-a (upper part), as well as for an intracellular RAS with the expression of cytosolic renin-b (lower part). Note that renin-a and renin-b are cell type specifically differentially expressed and not necessarily coexist in the same cell. Model C describes an intracellular RAS based on uptake of renin, angiotensinogen or ANGII from the extracellular space. RAS, renin-angiotensin system; ANG, angiotensin; AT1R, angiotensin receptor type 1; AT2R, angiotensin receptor type 2; AOGEN, angiotensinogen; RnBP, renin binding protein (N-acetyl-glucosamine epimerase); (P)RR, (pro)renin receptor (ATP6AP2); NO, nitric oxide; NF-ĸB, nuclear factor kappa-light-chain-enhancer of activated B cells; c-jun, cellular jun protooncogene; IGF1, insulin like growth factor 1; TGFß, transforming growth factor ß; Ncl, nucleus; Mito, mitochondrium; rER, rough endoplasmic reticulum; mtNO, mitochondrial NO; ROS, reactive oxygen species; oxphos, oxidative phosphorylation; ∆Ψm = mitochondrial membrane potential; ATP, adenosine triphosphate; Bcl2, B-cell lymphoma 2; PLA2, phospholipase A2; PTPs, protein tyrosin phosphatases; DAC, diacylglycerine; IP3, Inositoltrisphosphat; Ca, calcium; COX2, cyclooxygenase 2; NOX4, NADPH oxidase 4; MAPK, mitogen-activated protein kinase; Erk, extracellular signal-regulated kinase; p38, p38-mitogen-activated protein; JNK, Janus kinase; PAI-1 plasminogen activator inhibitor 1; PLZF promyelocytic leukemia zinc finger protein; M6P/IGF2 receptor, mannose-6-phosphate/insulin like growth factor 2 receptor. (For review see,[37]).
Primer sequences for detection of transcript abundances.
| Transcript | Forward primer | Revers primer |
|---|---|---|
| Renin exon(1–9) | ATGAATTCACCCCATTCAGC | CCAGATGGGCGGGAGGAGGATG |
| exon(1a-9) | TGAATTTCCCCAGTCAGTGAT | GAATTCACCCCATTCAGCAC |
| exon(2–9) | GCTCCTGGCAGATCACCAT | CCTGGCTACAGTTCACAACGTA |
| AGT | TGAGTTCTGGGTGGACA | GAGGAGGCGGGTTCTTTATC |
| AT1R | CGGCCTTCGGATAACATGA | CCTGTCACTCCACCTCAAAACA |
| AT2R | CAATCTGGCTGTGGCTGACTT | TGCCACTCACAGGTCCAAAGA |
| ACE | GCCCACCGACTCTACAACAT | ATGGGACACTCCTCTGTTGG |
| (P)RR | TGGGAAGCGTTATGGAGAAG | CTTCCTCACCAGGGATGTGT |
| RnBP | TTGCCTTCCTCATGGGTTAC | TCAGGTAGCCAAACCATTCC |
| YWHAZ | CATCTGCAACGACGTACTGTCTCT | GACTGGTCCACAATTCCTTTCTTG |